Certolizumab pegol for the treatment of Crohn's disease

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 6, 2011, Pages 375-389

  Schreiber, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Anti TNF; Certolizumab pegol; Crohn's disease; TNF inhibitors

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PLACEBO; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR;

ARTHRALGIA; BINDING AFFINITY; CORTICOSTEROID THERAPY; CROHN DISEASE; DAILY LIFE ACTIVITY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; JOB PERFORMANCE; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PRODUCTIVITY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW;

EID: 80054743856     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11413315     Document Type: Review

References (53)

1. Abbott Laboratories (2010) Humira [prescribing information]. North Chicago, IL: Abbott Laboratories.
2. Bernstein C.N. Fried M. Krabshuis J.H. Cohen H. Eliakim R. Fedail S. et al (2010) World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 16: 112–124.
3. Binion D.G. (2010) Biologic therapies for Crohn's disease: update from the 2009 ACG meeting. Gastroenterol Hepatol (N Y) 6(1 Suppl. 1)4–16.
4. Bourne T. Fossati G. Nesbitt A. (2008) A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn's disease: exploring a new mechanism of action. Bio Drugs 22: 331–337.
5. Centocor Ortho Biotech (2009) Remicade [prescribing information]. Malvern, PA: Centocor Ortho Biotech, Inc.
6. Clark M. Colombel J.-F. Feagan B.C. Fedorak R.N. Hanauer S.B. Kamm M.A. et al (2007) American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology 133: 312–339.
7. Colombel J.-F. Lémann M. Bouhnik Y. Dewit O. Dupas J.L. Mross M. et al (2010) Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: week 10 and 54 results of the MUSIC trial. Gastroenterology 138(5 Suppl. 1)S-166–S-166. (Abstract).
8. Colombel J.-F. Sandborn W.J. Rutgeerts P. Enns R. Hanauer S.B. Panaccione R. et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52–65.
9. Cominelli F. (2004) Cytokine-based therapies for Crohn's disease-new paradigms. N Engl J Med 351: 2045–2048.
10. Cosnes J. Nion-Larmurier I. Beaugerie L. Afchain P. Tiret E. Gendre J.P. (2005) Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54: 237–241.
11. D'Haens G. Baert F. van Assche G. Caenepeel P. Vergauwe P. Tuynman H. et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660–667.
12. Eddleston A. Marenzana M. Marshall D. Nesbitt A. (2009) Comparison of the distribution of an IGG and a pegylated Fab' form of an anti-TNFα antibody in the inflamed gut of colitic mice. Gut 58(Suppl. II)A305, (Abstract).
13. Feagan B. Sandborn W. Brown M. Brabant Y. Gerlier L. (2007) Confirmed benefits on work productivity and daily activities of certolizumab pegol in Crohn's disease patients: data from PRECiSE1. Gastroenterology 132(4 Suppl. 1)A507–A508. (Abstract).
14. Feagan B. Wolf D.C. Tan S. Brabant Y. Brown M. (2009 a) Certolizumab pegol treatment impacts hospitalizations and surgeries in Crohn's disease patients with prior failure to infliximab: results from WELCOME trial. Gut 58(Suppl. II)A470–A470. (Abstract).
15. Feagan B.G. Coteur G. Tan S. Keininger D.L. Schreiber S. (2009 b) Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 104: 1976–1983.
16. Feagan B.G. Reilly M.C. Gerlier L. Brabant Y. Brown M. Schreiber S. (2010) Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE2 study. Aliment Pharmacol Ther 31: 1276–1285.
17. Feagan B.G. Sandborn W.J. Wolf D.C. Coteur G. Purcaru O. Brabant Y. Rutgeerts P.J. (2011) Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. [ePub 12 January 2011].
18. Fernandez-Blanco I. Hinojosa J. (2008) Efficacy of intensification therapy with certolizumab pegol in Crohn's disease patients included in a compassionate-use program. Am J Gastroenterol 103(Suppl. I)S427–S427. (Abstract).
19. Fleischmann R. Vencovsky J. van Vollenhoven R.F. Borenstein D. Box J. Coteur G. et al (2009) Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 68: 805–811.
20. Hanauer S.B. Feagan B.G. Lichtenstein G.R. Mayer L.F. Schreiber S. Colombel J.-F. et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549.
21. Hanauer S.B. Panes J. Colombel J.-F. Bloomfield R. Schreiber S. Sandborn W.J. (2010) Clinical trial: impact of prior infliximab therapy on clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 32: 384–393.
22. Keystone E. Heijde D. Mason D. Landewé R. Vollenhoven R.V. Combe B. et al (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58: 3319–3329.
23. Krygier D.S. Ko H.H. Bressler B. (2009) How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. Expert Rev Gastroenterol Hepatol 3: 407–415.
24. Lamour S. Bracher M. Nesbitt A. (2009) Effect of PEG component of certolizumab pegol on simulated mast cell degranulation. Gut 58(Suppl. II)A305–A305. (Abstract).
25. Lichtenstein G. Thomsen O.Ø. Schreiber S. Lawrance I.C. Hanauer S.B. Bloomfield R. et al (2010 a) Long-term remission with certolizumab pegol in Crohn's disease: efficacy over 4 years in patients with no prior TNF-α inhibitor exposure (PRECISE 3 study). Gastroenterology 138, 5(Suppl.1)S-165–S-165. (Abstract).
26. Lichtenstein G.R. Hanauer S.B. Sandborn W.J. (2009) Management of Crohn's disease in adults. Am J Gastroenterol 104: 465–483.
27. Lichtenstein G.R. Thomsen O.Ø. Schreiber S. Lawrance I.C. Hanauer S.B. Bloomfield R. et al (2010 b) Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 8: 600–609.
28. Lichtiger S. Binion D.G. Wolf D.C. Present D.H. Bensimon A.G. Wu E. et al (2010) The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 32: 1228–1239.
29. MacDonald T.T. Hutchings P. Choy M.Y. Murch S. Cooke A. (1990) Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81: 301–305.
30. Nesbitt A. Fossati G. Bergin M. Stephens P. Stephens S. Foulkes R. et al (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis 13: 1323–1332.
31. Ng S.C. Plamondon S. Gupta A. Burling D. Kamm M.A. (2009) Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther 30: 757–766.
32. Porter C. Kopotsha T. Smith B.J. Nesbitt A.M. Urbaniak S.J. Armstrong-Fisher S.S. (2010) No significant transfer of certolizumab pegol with IgG in the perfused human placenta in vitro. Gastroenterology 138(Suppl. I)S-674–S-674. (Abstract).
33. Reilly M. Gerlier L. Brabant Y. Brown M. (2008) Validity, reliability and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 130: 393–404.
34. Reilly M.C. Brown M.C.J. Brabant Y. Gerlier L.C. Sandborn W.J. (2007) Defining the minimally important difference for WPAI:CD scores: what is a relevant impact on work productivity in active Crohn's disease? Gut 56(Suppl. III)A159–A159. (Abstract).
35. Reinecker H.C. Steffen M. Witthoeft T. Pflueger I. Schreiber S. MacDermott R.P. Raedler A. (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94: 174–181.
36. Rutgeerts P. Feagan B.G. Lichtenstein G.R. Mayer L.F. Schreiber S. Colombel J.-F. et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402–413.
37. Sadowski D.C. Bernstein C.N. Bitton A. Croitoru K. Fedorak R.N. Griffiths A. et al (2009) Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 23: 185–202.
38. Sandborn W. Vermeire S. Abreu M. D'Haens G. Colombel J.-F. Mitchev K. et al (2009) Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure to infliximab is not affected by concomitant medications. Am J Gastroenterol 104(Suppl. 3)S451–S452. (Abstract).
39. Sandborn W.J. Abreu M.T. D'Haens G. Colombel J.-F. Vermeire S. Mitchev K. et al (2010 a) Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 8: 696–702.
40. Sandborn W.J. Feagan B.G. Stoinov S. Honiball P.J. Rutgeerts P. Mason D. et al (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228–238.
41. Sandborn W.J. Schreiber S. Hanauer S.B. Colombel J.-F. Bloomfield R. Lichtenstein G.R. (2010 b) Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the precise 4 study. Clin Gastroenterol Hepatol 8: 696–702.
42. Sandborn W.J. Schreiber S. Hanauer S.B. Colombel J.-F. Bloomfield R. Lichtenstein G.R. (2010 c) Patients with Crohn's disease treated with certolizumab pegol experienced long-term remission regardless of prior TNF-α inhibitor exposure (PRECISE 4 study). Gastroenterology 138(5 Suppl. 1)S-9–S-9. (Abstract).
43. Schreiber S. Colombel J.-F. Bloomfield R. Nikolaus S. Schölmerich J. Panés J. et al (2010 a) Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of precise 2 randomized maintenance trial data. Am J Gastroenterol 105: 1574–1582.
44. Schreiber S. Khaliq-Kareemi M. Lawrance I. Thomsen O. Bloomfield R. Sandborn W. (2009) Rapid improvement of patient-reported CDAI diary components by day 8 in active Crohn's disease patients treated with certolizumab pegol. Am J Gastroenterol 104(Suppl. 3)S442–S442. (Abstract).
45. Schreiber S. Khaliq-Kareemi M. Lawrance I.C. Thomsen O.Ø. Hanauer S.B. Bloomfield R. et al (2010 b) Certolizumab pegol demonstrates efficacy in maintaining response and remission in patients with active Crohn's disease regardless of their immunosuppressant treatment status at entry to the PRECISE 2 study. Gastroenterology 138(5 Suppl. 1)S-165–S-165. (Abstract).
46. Schreiber S. Khaliq-Kareemi M. Lawrance I.C. Thomsen O.Ø. Hanauer S.B. McColm J. et al (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239–250.
47. Schreiber S. Lawrance I.C. Thomsen O.Ø. Hanauer S.B. Bloomfield R. Sandborn W.J. (2011) Randomized clinical trial: certolizumab pegol for fistulas in Crohn's disease–subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 33: 185–193.
48. Schreiber S. Nikolaus S. Hampe J. Hämling J. Koop I. Groessner B. et al (1999) Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 353: 459–461.
49. Schreiber S. Rutgeerts P. Fedorak R.N. Khaliq-Kareemi M. Kamm M.A. Boivin M. et al (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129: 807–818.
50. Smolen J. Landewe R.B. Mease P. Brzezicki J. Mason D. Luijtens K. et al (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68: 797–804.
51. UCB (2009) Cimzia [prescribing information]. Smyrna, GA: UCB, Inc.
52. van Assche G. Vermeire S. Rutgeerts P. (2010) The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol 7: 79–85.
53. Veronese F.M. Mero A. (2008) The impact of PEGylation on biological therapies. Bio Drugs 22: 315–329.